Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Continuous cardiac rhythm monitoring via cardiac implantable electronic devices finds an increased number of patients with asymptomatic atrial fibrillation. Yet, not all patients with device-detected atrial high-rate episodes are alike. Fine-tuning risk assessment may help identify those who can benefit most from anticoagulation.
Several experimental systems have been used over the past five decades to address important questions in cardiac development and congenital heart disease. Here we discuss the strengths and limitations of available models, and how the use of different models synergistically is needed for a deeper understanding of these complex diseases.
The US Food and Drug Administration (FDA) has approved sotagliflozin with a broad heart-failure indication, even in the absence of trial data in patients without diabetes. No one knows what the benefits or risks of inhibiting SGLT1 in the heart might be.
Sotatercept is the first successful therapy to make it through phase 3 to regulatory submission in pulmonary arterial hypertension that is not proposed to work via vasodilatory mechanisms. The phase 3 STELLAR study of sotatercept treatment challenges established thinking on pulmonary vascular remodeling and offers patients hope for a step change in outcomes.
Over recent decades, shifts toward translational or applied research in many countries have come at the expense of fundamental discovery research. Here we discuss the historical importance of basic science in the cardiovascular field, the risks in its decline and the ongoing need for a strong foundation in fundamental discovery research.
The rapid development of single-cell transcriptomics, epigenomics, proteomics and metabolomics has resulted in a wave of new biological discoveries. Here we explore what this has meant for the cardiovascular field and what the future might hold for developing treatments for patients.
Pregnancy is associated with a substantial risk of short-term and long-term cardiovascular diseases. Here we discuss physiological and social factors that affect the risk of pregnancy-related cardiovascular diseases and opportunities to improve outcomes.
Iron is essential to the production of myocardial energy and proteins critical for cardiovascular function. Nearly 50% of patients with heart failure with reduced ejection fraction (HFrEF) meet current criteria for iron deficiency, and there has been considerable interest in intravenous repletion of iron stores as a therapeutic strategy to improve HFrEF outcomes. However, the data on intravenous iron therapy in HFrEF have been mixed.
